Skip to the main content

Original scientific paper

https://doi.org/10.5562/cca4402

Comparative in vivo Safety Assessment of Surface-Engineered Gold Nanocarriers for Oral L-DOPA Delivery

Filip Vrban ; Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia
Vedran Dovečer ; General Hospital Varaždin, Varaždin, Croatia
Petra Dolenec ; University of Rijeka, Faculty of Medicine, Rijeka, Croatia
Anamaria Gojanović Rajić ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Maja Beus ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Lucija Božičević ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Nikolina Kalčec ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Nikolina Peranić ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Antonija Sulimanec ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Jasna Jurasović ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Ruža Frkanec ; University of Zagreb, Centre for Research and Knowledge Transfer in Biotechnology, Zagreb, Croatia
Vedran Micek ; Institute for Medical Research and Occupational Health, Zagreb, Croatia
Krešimir Rotim ; Neurospine Special Hospital, Zagreb, Croatia
Ivana Vinković Vrček ; University of Rijeka, Faculty of Medicine, Rijeka, Croatia *

* Corresponding author.


Full text: english pdf 8.142 Kb

versions

page P1-P12

downloads: 0

cite


Abstract

Gold nanoparticles (AuNPs) are among the most extensively investigated nanomaterials for targeted drug delivery owing to their unique physicochemical properties, versatile surface functionalisation, and potential to transport therapeutics across biological barriers. However, comprehensive in vivo safety data following repeated oral exposure remain limited, particularly for surface-stabilised AuNP formulations intended for oral drug delivery. In this study, we performed a comparative in vivo safety assessment of two AuNP formulations synthesized in the presence of peptidoglycan monomer (PGM) or adamantane (Ad), administered alone or following pre-incubation with
L-DOPA, in healthy male and female Wistar Han rats.
Animals received test substances daily by oral gavage for 28 days. Gold accumulation in major organs was quantified by inductively coupled plasma mass spectrometry (ICP-MS), and systemic safety was assessed by serum biochemical analyses together with measurements of reactive oxygen species (ROS) and reduced glutathione (GSH) in serum, liver, kidneys, and brain.
Repeated oral administration resulted in measurable, organ-specific gold accumulation, predominantly in the kidney and liver, without significant main effect of sex or treatment ×sex interaction on tissue distribution; gold was not detected in brain tissue. Biochemical alterations were more pronounced following Ad-AuNP administration, whereas PGM-AuNP exposure produced only limited changes in serum biochemical parameters. Mild changes in selected liver and kidney biomarkers were observed in some treatment groups but were not consistently accompanied by oxidative stress or widespread systemic toxicity, and tissue ROS and GSH levels indicated only modest redox perturbations.
These findings indicate that repeated oral exposure to PGM-AuNPs can result in organ-specific gold accumulation without marked systemic toxicity in healthy rats. Despite comparable primary size, morphology, hydrodynamic diameter, and ζ-potential, PGM-AuNPs and Ad-AuNPs elicited distinct biological responses, indicating that tissue gold burden and conventional physicochemical descriptors alone do not predict their in vivo biological behaviour. The favourable safety profile of PGM-AuNPs supports their continued preclinical development as oral L-DOPA nanocarriers, while pharmacokinetics, brain delivery efficiency, and therapeutic efficacy remain to be established in subsequent studies.

Keywords

nanosafety; gold nanoparticles; adamantane; peptidoglycan monomer; L-DOPA, Wistar rat

Hrčak ID:

353683

URI

https://hrcak.srce.hr/353683

Publication date:

12.11.2026.

Visits: 0 *